NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
"BACKGROUND AND OBJECTIVE:
Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of s...
Heterocyclic Compounds,
Receptors, CXCR4,
Hematopoietic Stem Cell Mobilization,
Lymphoma,
Multiple Myeloma,
Peripheral Blood Stem Cell Transplantation,
Receptors, CXCR4/antagonists & inhibitors,
Transplantation, Autologous,
Multiple Myeloma/therapy,
Lymphoma/therapy
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma
and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people
with myeloma by promoting the most effective tests and treatments for myeloma and its
complications....
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications. This guideline...
